13F Pro quality score
Rank #2,031 of 2,931
Rankings refresh quarterly once 80% of peers have filed. Next update: ~Feb 14, 2027.
Reported revenue, net income and operating margin by fiscal year, from SUPERNUS PHARMACEUTICALS, INC.'s annual filings on SEC EDGAR.
| Period | Form | Revenue | Net income | Op. marginOperating margin |
|---|---|---|---|---|
| FY 2025 | 10-K | $719.0M | $-38.5M | -8.7% |
| FY 2024 | 10-K | $1.2B | $7.0M | 3.2% |
| FY 2023 | 10-K | $1.1B | $-126.0M | -13.9% |
| FY 2022 | 10-K | $901.0M | $-44.0M | -9.0% |
| FY 2021 | 10-K | $579.8M | $53.4M | 14.8% |
| FY 2020 | 10-K | $520.4M | $127.0M | 33.4% |
Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.
SUPERNUS PHARMACEUTICALS, INC. (SUPN) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SUPN at 42.4/100 on a composite quality score built from its SEC filings, placing it at rank #2,031 of 2,931 stocks — the bottom half of the AI-ranked universe. SUPN scores in the top quartile across balance sheet strength (93.8), profitability (87.0). Areas of concern include institutional flow (0.1) and revenue growth (5.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 25.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q3 2026), SUPERNUS PHARMACEUTICALS, INC. reports quarterly revenue of $226.8M, net income of $20.9M, an operating margin of 9.3%. Top institutional holders of SUPN by reported 13-F value include BlackRock, VANGUARD PORTFOLIO MANAGEMENT, STATE STREET, based on the most recent SEC filings. SUPN trades on the Nasdaq exchange and files with the SEC under CIK 1356576. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SUPN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for SUPERNUS PHARMACEUTICALS, INC. directly from SEC EDGAR.
Financials through the period ended SEC EDGAR: CIK 1356576 →